66 related articles for article (PubMed ID: 18268287)
1. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
Terasawa T; Dahabreh IJ; Nihashi T
Oncologist; 2010; 15(7):750-9. PubMed ID: 20587551
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
[TBL] [Abstract][Full Text] [Related]
3. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on metals-based radioimmunotherapy (RIT): moving forward.
White JM; Escorcia FE; Viola NT
Theranostics; 2021; 11(13):6293-6314. PubMed ID: 33995659
[TBL] [Abstract][Full Text] [Related]
5. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Younes A; Hilden P; Coiffier B; Hagenbeek A; Salles G; Wilson W; Seymour JF; Kelly K; Gribben J; Pfreunschuh M; Morschhauser F; Schoder H; Zelenetz AD; Rademaker J; Advani R; Valente N; Fortpied C; Witzig TE; Sehn LH; Engert A; Fisher RI; Zinzani PL; Federico M; Hutchings M; Bollard C; Trneny M; Elsayed YA; Tobinai K; Abramson JS; Fowler N; Goy A; Smith M; Ansell S; Kuruvilla J; Dreyling M; Thieblemont C; Little RF; Aurer I; Van Oers MHJ; Takeshita K; Gopal A; Rule S; de Vos S; Kloos I; Kaminski MS; Meignan M; Schwartz LH; Leonard JP; Schuster SJ; Seshan VE
Ann Oncol; 2017 Jul; 28(7):1436-1447. PubMed ID: 28379322
[TBL] [Abstract][Full Text] [Related]
6. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.
Boswell CA; Brechbiel MW
Nucl Med Biol; 2007 Oct; 34(7):757-78. PubMed ID: 17921028
[TBL] [Abstract][Full Text] [Related]
7. [
Laszlo GS; Sandmaier BM; Kehret AR; Orozco JJ; Hamlin DK; Dexter SL; Lim SYT; Cole FM; Huo J; Wilbur DS; Walter RB
Leuk Lymphoma; 2023; 64(7):1335-1339. PubMed ID: 37170642
[No Abstract] [Full Text] [Related]
8. The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
Choi JH; Lim I; Byun BH; Kim BI; Choi CW; Kang HJ; Shin DY; Lim SM
PLoS One; 2022; 17(9):e0273839. PubMed ID: 36156599
[TBL] [Abstract][Full Text] [Related]
9. Early evaluation of tumor response to
Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
[TBL] [Abstract][Full Text] [Related]
10. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.
England CG; Rui L; Cai W
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):517-532. PubMed ID: 27844106
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET in Follicular Lymphoma Management.
Bodet-Milin C; Eugène T; Gastinne T; Frampas E; Le Gouill S; Kraeber-Bodéré F
J Oncol; 2012; 2012():370272. PubMed ID: 22899920
[TBL] [Abstract][Full Text] [Related]
12. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.
Cazaentre T; Morschhauser F; Vermandel M; Betrouni N; Prangère T; Steinling M; Huglo D
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):494-504. PubMed ID: 19820933
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
14. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Ulaner GA; Colletti PM; Conti PS
Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
[TBL] [Abstract][Full Text] [Related]
15. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
Spaepen K; Mortelmans L
Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
[TBL] [Abstract][Full Text] [Related]
17. Perspectives of molecular imaging and radioimmunotherapy in lymphoma.
Iagaru A; Goris ML; Gambhir SS
Radiol Clin North Am; 2008 Mar; 46(2):243-52, viii. PubMed ID: 18619379
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]